1Sakamoto J, Clin K, Kondo K, et al. Phase I1 study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer [J].Anticancer Drugs,2006;17 (2): 231-6.
2Hong YS, Song SY, Lee SI, et al. A phase II trail of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer [J].Ann Oncol, 2004;15(9) : 1344-7.
3Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients [J]. Cancer Chemother Pharmacol, 2000:45(4) :291-7.
4Sileri P, Dugo S, Bennavoli D,et al. Metachronous splenicmetastasis from colonic carcinoma five years after surgery : a case report and literature review[ J]. South Med J ,2009 ; 102 (7) :733-5.
5Kweekel DM. Antonini NF. Nortier JW, et al. Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array[ J]. Br J Cancer, 2009;101(2) :357-62.
6Cohen P. Overview of the IGF-I system. Horm Res ,2006,65 ( 1 ) : 3-8.
7Wu Y,Yakar S,Zhao L,et al. Circulating insulin-like growth fac- tor-I levels regulate colon cancer growth and metastasis. Cancer Res,2002,12(62) : 1030-1035.
8Jones JI,Clemmons DR. Insulin-like growth factors and their bind-ing proteins :biological functions. Endocr Rev, 1995,20(13) : 3-34.
